Clinical outcomes of reperfusion therapy in patients with site-specific basilar artery occlusion

医学 溶栓 改良兰金量表 病因学 闭塞 置信区间 冲程(发动机) 大脑中动脉 外科 内科学 回顾性队列研究 优势比 心脏病学 缺血 缺血性中风 心肌梗塞 工程类 机械工程
作者
Nina Žakelj,Igor Rigler,Alja Longo,Senta Frol,Janja Pretnar Oblak
出处
期刊:Journal of NeuroInterventional Surgery [BMJ]
卷期号:17 (11): 1249-1253 被引量:3
标识
DOI:10.1136/jnis-2024-022065
摘要

Background Despite its low incidence, basilar artery occlusion (BAO) remains a major therapeutic challenge since severe disability and death occur in about 80% of patients. Specific site of BAO (proximal, middle, or distal) has rarely been reported as a prognostic factor in reperfusion therapy. We aimed to explore the relationship between site-specific BAO and clinical outcomes in patients treated with reperfusion therapies. Methods We performed a single-centre retrospective study of all consecutive patients with acute BAO admitted to the University Medical Centre Ljubljana between January 2013 and August 2022 who were treated with reperfusion therapies. Patients were grouped according to the location of BAO and compared for baseline characteristics, differences in stroke aetiology, type of reperfusion therapy, success of recanalization, and clinical outcome after 90 days evaluated by the modified Rankin Scale (mRS) score. Statistical analysis was performed with the two-sided ANOVA t-tests for continuous measures, Chi-squared (χ2) tests for categorical measures and a multivariate ordinal logistic regression analysis. Results The study included 103 patients (47% females, median age 74 years; confidence interval (CI) 72 to 98). Proximal BAO was found in 13%, middle in 13%, and distal in 74% of patients. Cardioembolic etiology was more common in distal (=0.01), and atherosclerotic etiology in proximal and middle BAO occlusions (P=0.02). While distal BAO was more likely to be recanalized using intravenous thrombolysis (IVT) compared with other sites of occlusion (P=0.05), we found no difference between different occlusion sites and the success of endovascular treatment (EVT). Lower age (odds ratio (OR) 0.89; CI 0.84 to 0.95; P<0.01) and shorter time to intervention (OR 0.71; CI 0.53 to 0.95; P=0.02), regardless of it being IVT or EVT, were predictors of an excellent clinical outcome (mRS 0–2). Distal occlusion (OR 28; CI 2.7 to 300; p<0.01) was a strong predictor of a favorable clinical outcome (mRS 0–3). Conclusion Prompt reperfusion, regardless of it being IVT or EVT, increases the chance of excellent clinical outcomes in patients with acute BAO. Distal BAO is more often associated with a favorable clinical outcome compared with the proximal and middle segments.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
大个应助阿飞采纳,获得30
4秒前
空气完成签到,获得积分10
6秒前
wjp完成签到 ,获得积分10
7秒前
倒立拉shi完成签到,获得积分10
8秒前
334niubi666完成签到 ,获得积分10
9秒前
9秒前
11秒前
savesunshine1022完成签到,获得积分10
11秒前
11秒前
11秒前
FashionBoy应助中午吃什么采纳,获得10
11秒前
MFX完成签到,获得积分10
12秒前
从容的星月完成签到,获得积分10
12秒前
爆米花应助落叶归根采纳,获得10
14秒前
诚心的雪瑶完成签到,获得积分10
15秒前
冒险寻羊发布了新的文献求助10
16秒前
莫小丫完成签到 ,获得积分10
16秒前
16秒前
tzy完成签到,获得积分10
18秒前
18秒前
WWW发布了新的文献求助10
19秒前
19秒前
风凌渡完成签到,获得积分10
20秒前
白河应助姬昌采纳,获得10
21秒前
风轩轩发布了新的文献求助10
21秒前
21秒前
上官若男应助香辣沙河粉采纳,获得10
22秒前
感性的神级完成签到,获得积分0
23秒前
23秒前
23秒前
23秒前
24秒前
结实寒风完成签到,获得积分10
25秒前
坦率灵槐完成签到,获得积分10
26秒前
蜗牛发布了新的文献求助10
27秒前
27秒前
欧气青年完成签到,获得积分10
27秒前
28秒前
南宫书瑶发布了新的文献求助10
29秒前
JamesPei应助孤独的醉易采纳,获得10
29秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
The Organometallic Chemistry of the Transition Metals 800
Chemistry and Physics of Carbon Volume 18 800
The Organometallic Chemistry of the Transition Metals 800
Leading Academic-Practice Partnerships in Nursing and Healthcare: A Paradigm for Change 800
The formation of Australian attitudes towards China, 1918-1941 640
Signals, Systems, and Signal Processing 610
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6437813
求助须知:如何正确求助?哪些是违规求助? 8252122
关于积分的说明 17558751
捐赠科研通 5496227
什么是DOI,文献DOI怎么找? 2898713
邀请新用户注册赠送积分活动 1875376
关于科研通互助平台的介绍 1716364